Think Bioscience

Think Bioscience is a biotechnology company that uses synthetic biology to develop small-molecule drugs for historically challenging therapeutic targets. The company’s platform combines applied microbiology, enzymology, and data science to uncover novel mechanisms of biomolecular engagement, leveraging the cell as a chemical processor with capabilities that surpass digital systems. By using synthetic biology to identify and optimize small molecules, Think Bioscience aims to drug targets that have proven difficult or impossible to address with conventional approaches. The company focuses on targets in genomics, microbiome therapeutics, and metabolic diseases. Founded in 2019 and headquartered in Boulder, Colorado, Think Bioscience has raised approximately $26 million in Series A funding. Investors include Innovation Endeavors, Xora Innovation, AV8 Ventures, Regeneron Ventures, Janus Henderson Investors, MBX Capital, CU Healthcare Innovation Fund, Wireframe Ventures, and America’s Seed Fund. The company has approximately 31 employees.